Scientific Excellence

Scientific Publications

Discover our latest research contributions advancing the fields of AI-driven drug discovery, STAT3 biology, and translational medicine.

Research Categories

Explore our scientific publications across our key research domains

STAT3 Biology

Fundamental insights into the structure and function of STAT3, exploring its role in cellular signaling pathways and disease progression.

AI in Drug Discovery

Innovative computational approaches leveraging machine learning and AI to accelerate the identification and optimization of novel therapeutic candidates.

Clinical Research

Translational and clinical studies evaluating the safety, efficacy, and mechanisms of TTI-101 and related compounds in various disease models and patient populations.

Featured Publications

Highlighting our most impactful research contributions

STAT3 BiologyNature Communications

Targeting the SH2 Domain of STAT3 with Small Molecule Inhibitors for Cancer Therapy

A comprehensive analysis of the structural interactions between TTI-101 and the SH2 domain of STAT3, providing insights into the molecular basis for selective inhibition.

Horner T, et al.
March 2025
284 Citations
AI in Drug DiscoveryScience Advances

AI-Driven Discovery of Novel STAT3 Inhibitors for Fibrotic Diseases

Application of our proprietary deep learning platform to identify novel small molecule inhibitors targeting STAT3 with enhanced specificity and reduced off-target effects.

Devasini L, Costa S, et al.
January 2025
192 Citations
Clinical ResearchNew England Journal of Medicine

Preliminary Results of TTI-101 in Patients with Idiopathic Pulmonary Fibrosis

Interim analysis of the RENEW-IPF Phase 2 clinical trial demonstrating promising safety and efficacy signals in patients with IPF.

Milner S, Horner T, et al.
June 2025
95 Citations

Research Timeline

A chronological journey of our key scientific publications

2018

First STAT3 Structural Analysis

Published our foundational research on the structural characterization of STAT3 in complex with DNA
2020

AI Platform Development

Introduction of our proprietary AI platform for accelerated target identification and drug discovery
2022

TTI-101 Preclinical Efficacy

Key publications demonstrating the preclinical efficacy of TTI-101 in models of fibrosis and HCC
2023

Phase 1 Clinical Results

Publication of Phase 1 safety and pharmacokinetic data for TTI-101 in healthy volunteers
2025

RENEW-IPF Interim Analysis

Recent publication of promising interim results from our Phase 2 trial in IPF patients

Impact & Metrics

Measuring our research influence across the scientific community

28

Total Publications

950+

Total Citations

12

Journal Covers

Research Collaborations

We actively seek partnerships with academic institutions, research organizations, and industry leaders to advance our understanding of disease mechanisms and accelerate therapeutic development.